Roswin Indications/Uses

Dyslipidemia: In adult patients, rosuvastatin is indicated to: Decrease elevated total cholesterol (total-C), LDL-cholesterol (LDL-C) and triglycerides (TG) and to increase high density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia (Fredrickson types IIa and IIb). Rosuvastatin also decreases Apo B, non-HDL-C, VLDL-C, VLDL-TG, LDL-C/HDL-C, total-C/HDL-C, non-HDL-C/HDL-C, and Apo B/Apo A-I ratios and increases Apo A-I.
Treat isolated hypertriglyceridemia (Fredrickson type IV hyperlipidemia).
Treat patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia).
Decrease total-C and LDL-C in patients with homozygous familial hypercholesterolemia as adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable.
Slow the progression of atherosclerosis as part of a treatment strategy to decrease total-C and LDL-C to target levels.
In children and adolescent patients 10 to 17 years old, rosuvastatin is indicated to: Decrease total-C, LDL-C and Apo B levels in children and adolescents 10 to 17 years old (boys Tanner Stage II and above, and girls who are at least one year post-menarche) with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C >190 mg/dL or LDL-C >160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular risk factors are present in the patient.
Primary Prevention of Cardiovascular Disease: In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age (≥50 years old in men and ≥65 years old in women), hsCRP ≥2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease, rosuvastatin is indicated to: Decrease the risk of stroke; decrease the risk of myocardial infarction; decrease the risk of arterial revascularization procedures.